🔎 Trials Near Me

Home › Major Depressive Disorder › NCT05523817

Targeting Specific Brain Networks to Treat Specific Symptoms in Depression

RecruitingHealthy volunteers welcome

Probing the Functional and Behavioral Impact of Precision Circuit Modulation in Neuropsychiatric Diseases

Who can join

Ages 18 to 65 · All sexes · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria for healthy participants:

* 18-65 years of age
* Capacity to provide informed consent form to participate in the study

Inclusion Criteria for participants with Major Depressive Disorder (MDD):

* 18-65 years of age
* Capacity to provide informed consent form to participate in the study
* Currently in a major depressive episode. Comorbid anxiety disorders and personality disorders will be allowed provided that MDD is the primary diagnosis.

Exclusion Criteria for all participants:

* Meeting criteria, in the past or currently, for bipolar affective disorder, hypomania or mania.
* Meeting criteria, in the past or currently, for a primary psychotic disorder (e.g., schizophrenia).
* Neurological conditions with known structural brain lesions, e.g., intracranial masses, multiple sclerosis.
* Any personal history of seizures or a family history of epilepsy in a first-degree relative.
* Metal in the body that is ferromagnetic or metallic injury to the eyes.
* Implanted pacemakers, medication pumps, vagal stimulators, deep brain stimulators, or ventriculoperitoneal shunts, etc.
* Substance abuse or dependence that is current and active within the last six months, as indicated by self-report (e.g., heroin, cocaine, methamphetamines).
* Inability to meet the safety criteria for MRI scanning for any other reason.
* Severe or unstable medical illness.
* Currently pregnant, as assessed with urine pregnancy test in women of childbearing age.

About the study

Repetitive transcranial magnetic stimulation (rTMS) is a way of non-invasively stimulating specific brain networks and is an established treatment for Major Depressive Disorder (MDD). This proposal will reveal network mechanisms of the therapeutic effects of rTMS by investigating how stimulating each network specifically changes network connectivity and behavior. This will be done in a highly individualized manner in depressed and healthy patients, leading to more effective and more individualized treatments for depression.

What is being tested

Sponsor: Massachusetts General Hospital · Participants: 80 · Started: Mar 12, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT05523817

Locations in the U.S.

MassachusettsMassachusetts General Hospital, Boston

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.